A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
Lung Cancer, 07/11/2012
Clinical Article
Dowell JE et al. – This trial evaluating the addition of bevacizumab to cisplatin and pemetrexed in patients with previously untreated, advanced Malignant mesothelioma (MM) failed to meet the primary endpoint of a 33% improvement in the progression–free survival rate at 6months compared with historical controls treated with cisplatin and pemetrexed alone.



